BNGO Bionano Genomics, Inc.
Price Chart
Executive Summary
Alka Chaubey, Ph.D., resigned as Chief Medical Officer of Bionano Genomics, effective July 5, 2026. The filing provides no reason for the departure and no replacement is named, which is a minor negative signal for the company's executive bench depth.
Actionable Insight
The CMO departure without a named successor adds uncertainty around the company's clinical strategy at a time when Bionano (market cap ~$14M) appears to be resource-constrained. Monitor for a replacement announcement and any related departure of other key officers. If no successor is named within two months, the risk of broader talent attrition increases.
Key Facts
- Alka Chaubey resigned as Chief Medical Officer effective July 5, 2026.
- No reason for resignation was given (no retirement, no new role).
- No successor or interim replacement was named.
- The company has an interim CEO (Albert A. Luderer, Ph.D.), per the signature block.
- BNGO has a market cap of ~$14M and is traded on the Nasdaq Capital Market.
Financial Impact
Not quantifiable — the filing contains no financial figures.
Risk Factors
- Loss of key clinical leadership could delay regulatory or product milestones.
- No announced replacement suggests potential difficulty in attracting qualified candidates or cost-cutting measures.
- The company already has an interim CEO — multiple interim roles signal organizational instability.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001411690-26-000036 |
| Document: 0001411690-26-000036-index-headers.html | 0001411690-26-000036 |
| Document: 0001411690-26-000036-index.html | 0001411690-26-000036 |
| Document: 0001411690-26-000036.txt | 0001411690-26-000036 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
8-K
| $1.18 awaiting T+5 | awaiting T+5 | — | $1.16 (+1.28%) |
|
May 28, 2026
15d ago
|
8-K
| $1.25 $1.30 | ▲ +4.00% | ▲ +4.05% | $1.16 (−7.20%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $1.18 $1.17 | ▲ +0.85% | ▲ +0.42% | $1.16 (+1.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access